We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Structure of Enzyme for Trehalose Synthesis May Promote Drug Development

By LabMedica International staff writers
Posted on 29 Jun 2016
A team of molecular microbiologists has established the molecular structure of an enzyme required for synthesis of trehalose, a sugar required by several different pathogenic fungi.

To survive in the human host, pathogenic fungi require the disaccharide trehalose, which is formed by a 1,1-glucoside bond between two alpha-glucose units. More...
Trehalose acts to protect the fungi from the high temperatures they experience while trying to colonize the human organism. The enzymes that synthesize trehalose are not found in humans, and thus serve as potential targets for novel antifungal drugs.

Investigators at Duke University (Durham, NC, USA) used x-ray crystallography to establish multiple structures for one of the trehalose biosynthetic enzymes, trehalose-6-phosphate phosphatase (Tps2), from Candida albicans.

In a paper published in the June 15, 2016, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences the investigators said that these structures and germane in vivo and biochemical studies revealed the significance of the Tps2 N-terminal domain in fungal cellular stress responses and the conformational flexibility of the Tps2 C-terminal domain that imposed exquisite substrate specificity and permitted efficient catalysis.

"We found that the active site of this enzyme is identical in each of these pathogenic fungi, so they all use the same mechanism and have the same residues that are necessary for the production of trehalose," said senior author Dr. Richard G. Brennan, professor of biochemistry at Duke University. "By targeting those active sites, we hope to create a drug with broad-spectrum effect. If you could kill one fungus, you are going to kill them all; at least if you can get the drug inside."

Related Links:
Duke University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.